ACST (acastipharma.com) מכפיל P/S עתידי

Acasti Pharma (ACST) possesses significant potential in the therapy of rare neurocardiological pathologies through safe inhalation agents. The forward P/S valuation reflects market expectations, with the value fixed at . Patent control over orphan molecules in oncology guarantees pricing power. Current focus is centered on the preparation of Phase 3 data for the drug ONP-002 to undergo a regulatory audit.

To find fundamental support, it is crucial for an investor to evaluate the ratio of current market capitalization to projected revenue, which allows them to distinguish an undervalued asset from a degrading business via the company's expected P/S chart. In the case of Acasti Pharma (ACST), this indicator measures market value relative to potential revenues from partnerships in the development of cardiology drugs, confirming the biotech startup's M&A attractiveness and eliminating the risk of a value trap.